Pfizer Lipitor counterfeit crackdown
Executive Summary
Pfizer directs FDA to three lots of counterfeit Lipitor (atorvastatin) recalled by Albers Medical Distributors. Pfizer's help is part of an agreement between Pharmaceutical Research & Manufacturers of America member companies and FDA that companies will alert FDA Office of Criminal Investigations of suspected counterfeit drugs within five working days (1"The Pink Sheet" April 28, 2003, In Brief)...
You may also be interested in...
Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1
Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida
PhRMA counterfeit reporting program
Pharmaceutical Research & Manufacturers of America member companies will notify FDA Office of Criminal Investigations of suspected counterfeit drugs "within five working days" under voluntary agreement announced April 22. Program was developed by PhRMA's FDA Key Issues Committee and will go into effect May 1. FDA and PhRMA will assess the program for possible improvements after one year, agency says...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.